GoodRx goes toe-to-toe with Hims, Ro as it push­es in­to ED treat­ment

5 weeks ago
Pharma
Health Tech

For­mer a16z biotech in­vest­ment leader Vi­jay Pande ex­its the VC firm

5 weeks ago
People

Ex­clu­sive: Scor­pi­on spin­out gets $177M for stealthy pipeline amid Chi­na com­pe­ti­tion

5 weeks ago
Financing
Startups

Re­cur­sion to lay off 20% of staff, a month af­ter slash­ing its pipeline

5 weeks ago
People
AI

Odyssey pulls back from IPO plans as pub­lic mar­kets re­main frozen

5 weeks ago
Financing
Startups

Up­dat­ed: HHS chief Kennedy re­moves all ACIP mem­bers, dis­man­tling vac­cine board

Last month
Pharma
FDA+

Biotech slump forces Re­silience to wind down six man­u­fac­tur­ing sites, us­ing bank­rupt­cy move

Last month
People
Manufacturing

FDA re­in­states gener­ic drug pol­i­cy group let go in April fir­ings

Last month
FDA+

For­mer HHS lawyer on No­vavax de­lay: Mix­ing pol­i­tics and ap­provals 'im­per­il­s' pub­lic health

Last month
FDA+

FDA adds bio­mark­er lim­its to stom­ach, esophageal can­cer la­bels for Mer­ck­'s Keytru­da and BM­S' Op­di­vo

Last month
Pharma
FDA+

Up­dat­ed: Mer­ck wins FDA ap­proval for RSV an­ti­body drug, mak­ing a hot mar­ket more com­pet­i­tive

Last month
R&D
Pharma

In a break from oth­er biotechs, Twist Bio­science throws sup­port be­hind tar­iffs on syn­thet­ic DNA

Last month
Pharma
Manufacturing

Fed­er­al­ly-fund­ed can­cer re­search comes to a per­ilous cross­roads

Last month
Bioregnum
R&D

Mer­ck says its oral PC­SK9 in­hibitor ‘sig­nif­i­cant­ly’ cut cho­les­terol in two Phase 3 tri­als

Last month
R&D

NewAms­ter­dam's ex­per­i­men­tal cho­les­terol drug re­duces pres­ence of Alzheimer's bio­mark­er

Last month
R&D

Avid­i­ty to seek ac­cel­er­at­ed ap­proval for FSHD drug; Ax­some to run an­oth­er tri­al

Last month
News Briefing

Met­sera shares ear­ly da­ta on an­ti-obe­si­ty amylin can­di­date

Last month
Startups
R&D

Who are the women re­shap­ing bio­phar­ma R&D? Nom­i­nate them for End­points' an­nu­al re­port

Last month
Special

Sanofi leans in­to 'first-mover ad­van­tage' by ship­ping Bey­for­tus ear­ly, as RSV an­ti­body mar­ket set to heat up

Last month
Pharma
Manufacturing

High­lights from #AS­CO25; Biotech’s icy mar­ket; Sanofi’s $9B ac­qui­si­tion; and more

Last month
Weekly

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

Last month
Pharma
FDA+

Up­dat­ed: Oma­da Health rose 21% in its pub­lic mar­ket de­but

Last month
Financing
Health Tech

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

Last month
R&D

Kelun's $250M PIPE; Val­ne­va moves chikun­gun­ya vac­cine to Phase 3 for kids

Last month
News Briefing
First page Previous page 9101112131415 Next page Last page
A service from the Financial Times